Bloomberg: Popular drugs for diabetes and obesity were linked to sharply lower rates of addiction and overdose in a large study of US veterans.
The study found that patients who started a GLP-1 receptor agonist were less likely to develop substance use disorders over the next three years than those who started an SGLT-2 inhibitor…